Streptococcal Infections
Recent clinical, regulatory, research and industry developments relating to this disease.
Increase in invasive group A streptococcal infection notifications, England, 2022.
Human Streptococcus suis outbreak, Sichuan, China.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 2 clinical trials expected to report results, the earliest in Q4 2026.
- Q4 2026A Phase 1 Randomized, Placebo-controlled, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the GSK 4-component Vaccine Against Group A Streptococcus Pyogenes (Strep A) With Alum or AS37 in Healthy Adults 18 to 25 Years of Age in Australia
- Q1 2027A Phase III, Observer-blind, Randomized Controlled Trial to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)
Clinical MilestonesViewHide
- 2026-02-27A Phase III, Observer-blind, Randomized Controlled Trial to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)Results expected Q1 2027
- 2025-08-11A Phase 1 Randomized, Placebo-controlled, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the GSK 4-component Vaccine Against Group A Streptococcus Pyogenes (Strep A) With Alum or AS37 in Healthy Adults 18 to 25 Years of Age in AustraliaResults expected Q4 2026
- 2026-02-27ClinicalA Phase III, Observer-blind, Randomized Controlled Trial to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)Results expected Q1 2027
- 2025-09-05ClinicalA Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Doses of Group B Streptococcus Vaccine (GBS NN/NN2 With Alhydrogel®) in Elderly Participants Aged 55 to 75Results posted
- 2025-08-26ClinicalA Phase I/II, Observer-Blind, Randomized, Placebo-Controlled, Dose-Selection Study to Assess the Safety, Tolerability, and Immunogenicity of Hexavalent Group B Streptococcus Conjugate Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age (WOCBA) in the US and South Africa.Primary completion
- 2025-08-11ClinicalA Phase 1 Randomized, Placebo-controlled, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the GSK 4-component Vaccine Against Group A Streptococcus Pyogenes (Strep A) With Alum or AS37 in Healthy Adults 18 to 25 Years of Age in AustraliaResults expected Q4 2026
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Streptococcal Infections5
- Anti-Bacterial Agents1
- Bacteremia1
- Chorioamnionitis1
- Disease Outbreaks1
- Endocarditis1
- Pneumonia1
- Streptococcus pyogenes1
Leading journals6
- American journal of reproductive immunology (New York, N.Y. : 1989)1
- Circulation1
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America1
- EBioMedicine1
- Emerging infectious diseases1
- Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin1
Leading researchers8
- Ainonen S1
- Aragon V1
- Aronoff DM1
- Axler O1
- Baddour LM1
- Balmer AJ1
- Baltimore RS1
- Barsic B1
Affiliations (unnormalised)6
- Aix Marseille University1
- ANMCO Research Center1
- Anthea Hospital1
- Bichat Hospital1
- Calvin University1
- Cancer Research UK Manchester Institute1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Streptococcal infections are infections caused by bacteria in the genus Streptococcus. The grounding supports their consideration across diagnosis, epidemiology, microbiology, complications, and veterinary contexts.
The cause is infection with bacteria of the genus Streptococcus. The supplied material does not support a more specific aetiologic breakdown by species or transmission route.
The grounding supports a bacterial infectious process due to Streptococcus, with complications that can include infective endocarditis. Beyond that, the supplied material does not provide enough detail to describe the biological mechanism more specifically.
The supplied material does not identify specific risk factors for streptococcal infections in general. It does note that infective endocarditis epidemiology includes healthcare-associated factors that predispose to infection, but this is specific to that complication rather than to streptococcal infections overall.
The supplied material does not provide a general treatment standard for streptococcal infections as a whole. It does support antimicrobial therapy and management of complications in the setting of infective endocarditis, but not a broader disease-level treatment description.
AI-generated summary grounded in MeSH and 1 peer-reviewed source. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Infections with bacteria of the genus STREPTOCOCCUS.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.